We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Lab21 Acquires Business and Assets of Delphic Diagnostics

By LabMedica International staff writers
Posted on 04 Dec 2009
Lab21, (Cambridge, UK) the healthcare diagnostics company, has acquired business and assets of Delphic Diagnostics (London, UK), a specialist laboratory services business with expertise in human immunodeficiency virus (HIV) and hepatitis. More...
The financial details of the acquisition have not been disclosed.

Delphic's business is focused on personalized medicine and companion diagnostics. It has developed a world leading expertise in pharmacology, virology, therapeutic drug monitoring, and specialist clinical trial services to the pharmaceutical industry. It has laboratories in Liverpool and in Kent and partner laboratories across Europe. It has strong quality accreditations, with more than 200 National Health Service (NHS; UK) customers and partnerships with various global pharmaceutical manufacturers.

Graham Mullis, CEO of Lab21, commented, "This acquisition is highly complementary to Lab21's existing business in companion diagnostics, and significantly extends our laboratory capacity and service offering in virology." Mr. Mullis added, "This acquisition is the latest step in our buy-and-build strategy and reinforces our market leadership position in molecular diagnostic services in the UK, specifically in the rapidly growing market for companion diagnostics."

Lab21 supplies tests and services across a broad range including pharmacogenetic tests, gold-standard viral diagnostics, cytochrome P450 genotyping, and viral resistance mapping

Related Links:
Lab21
Delphic Diagnostics


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Francisella Tularensis Test
TULAREMIA VIRCLIA IgG+IgM MONOTEST
New
HAV Rapid Test
OnSite HAV IgG/IgM Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.